Read by QxMD icon Read


Esmail Abej, Wael El-Matary, Harminder Singh, Charles N Bernstein
Objectives. To determine the relationship between fecal calprotectin (FCAL) and imaging studies and other biochemical inflammatory markers and the impact of FCAL measurements on decision-making in IBD patient management in usual clinical practice. Methods. 240 persons with IBD were enrolled. The correlation between FCAL values and other markers for disease activity such as serum albumin (alb), hemoglobin (Hg), and C-reactive protein (CRP) and diagnostic imaging or colonoscopy was examined. FCAL ≥ 250 mcg/g of stool was considered a positive result indicating active IBD...
2016: Canadian Journal of Gastroenterology & Hepatology
Marianne Williams, Yvonne Barclay, Rosie Benneyworth, Steve Gore, Zoe Hamilton, Rudi Matull, Iain Phillips, Leah Seamark, Kate Staveley, Steve Thole, Emma Greig
BACKGROUND: Irritable bowel syndrome (IBS) costs the National Health Service almost £12 million per annum. Despite national guidelines advising primary care management, these have failed to stem secondary care referrals of patients with likely IBS for unnecessary and costly assessment and investigation without necessarily achieving resolution of their symptoms. METHODS: In 2011, an integrated team from primary and secondary care developed a business case using baseline data to create a Somerset-wide IBS pathway using Clinical Commissioning Group funding...
October 2016: Frontline Gastroenterology
Anton Emmanuel, Darryl Landis, Mark Peucker, A Pali S Hungin
OBJECTIVE: To determine rates of faecal biomarker results capable of suggesting potentially treatable causes of irritable bowel syndrome (IBS) symptomatology in a population of patients with symptoms of IBS who meet Rome III criteria for that condition. DESIGN: Descriptive, retrospective study in which faecal biomarker results (dichotomised into 'normal' and 'abnormal' values) were related to data from patient-completed questionnaire data identifying demographics, Rome III criteria for IBS and IBS phenotype (IBS-D, IBS-C, IBS-M and IBS-U)...
October 2016: Frontline Gastroenterology
Abbas Shahsavari, Mehdi Azad, Naser Mobarra, Koorosh Goodarzvand Chegini, Nematollah Gheibi
Calprotectin is member of the S-100 protein family with a wide plethora of intra-and extracellular functions. Anticancer activities, antimicrobial effects and being a qualified disease marker are among the compelling features of this protein to be used as a pharmaceutical agent. However, there are several impediments to applications of protein pharmaceuticals including: proteolytic degradation, short circulating half-life, low solubility and immunogenicity. Pegylation is a common bioconjugation polymer capable of overcoming these drawbacks...
October 18, 2016: Protein Journal
Francesca Palone, Roberta Vitali, Salvatore Cucchiara, Maurizio Mennini, Alessandro Armuzzi, Daniela Pugliese, Renata DʼIncà, Brigida Barberio, Laura Stronati
BACKGROUND: Fecal high mobility group box 1 (HMGB1) has been suggested to be a novel noninvasive biomarker of gut inflammation. We aimed to assess the reliability of fecal HMGB1, compared with fecal calprotectin (FC), in detecting intestinal inflammation in pediatric and adult patients with inflammatory bowel disease (IBD) and to evaluate the accuracy of HMGB1 in identifying patients with IBD in clinical and endoscopic remission who still have histologic features of inflammation. METHODS: Stool samples from 85 children with IBD (49 Crohn's disease [CD] and 36 ulcerative colitis [UC] and 119 adults [57 Crohn's disease and 62 ulcerative colitis]) were analyzed for the study...
October 13, 2016: Inflammatory Bowel Diseases
Evangelos A Russo, Sameer Khan, Ryan Janisch, Roger N Gunn, Eugenii A Rabiner, Stuart A Taylor, Paul M Matthews, Timothy R Orchard
BACKGROUND: Fluorine-fluorodeoxyglucose positron emission tomography (F-FDG PET) has recently attracted interest for the measurement of disease activity in Crohn's disease (CD). The aim of this study was to assess the utility of FDG-PET as a marker of progression of inflammatory activity and its response to treatment in patients with CD. METHODS: Twenty-two patients with active CD were recruited prospectively to undergo FDG-PET scanning at 2 time points. All 22 index scans were used to assess sensitivity and specificity against a reference standard magnetic resonance imaging measure...
November 2016: Inflammatory Bowel Diseases
Natália A Borges, Amanda F Barros, Lia S Nakao, Carla J Dolenga, Denis Fouque, Denise Mafra
OBJECTIVE: Protein-bound uremic toxins from gut microbiota tend to accumulate in chronic kidney disease (CKD) patients and are poorly removed by current dialysis techniques. These toxins induce inflammation and are associated with cardiovascular disease (CVD). The aim of this study was to report the relationship between uremic toxins and inflammatory and cardiovascular markers in CKD patients. DESIGN: This was a cross sectional study. SUBJECTS: Twenty-one nondialysis patients were included (43% men, 63...
November 2016: Journal of Renal Nutrition
Margot Taks, Phillipe A R R Pijls, Luc J J Derijks, Robert Ten Broeke, Rene J Grouls, Joyce Curvers, Lennard P L Gilissen
INTRODUCTION: The effective, but expensive, drug infliximab is used in patients with inflammatory bowel disease (IBD). Monitoring infliximab trough levels and anti-infliximab antibody (ATI) formation can lead to a more cost-effective use of infliximab therapy. The aim of our study was to investigate the effect of implementation of a treatment algorithm for infliximab in a single-centre IBD cohort, focussing on remission rates and drug costs. METHODS: IBD patients aged 18 years or older treated with infliximab were asked to participate in this study...
October 4, 2016: European Journal of Gastroenterology & Hepatology
Gabriela M Balarini, Eliana Zandonade, Leandro Tanure, Gilda A Ferreira, Wildner M Sardenberg, Érica V Serrano, Cleia C Dias, Túlio P Navarro, Hilde H Nordal, Piotr M Mydel, Johan G Brun, Karl A Brokstad, Eva Gerdts, Roland Jonsson, Valéria Valim
OBJECTIVES: We aimed to identify the association of carotid atherosclerosis with the traditional risk factors, disease features, cytokine profile, and calprotectin in patients with primary Sjögren's syndrome (pSS). METHODS: 63 primary pSS patients and 63 age- and sex-matched healthy controls underwent carotid ultrasound, clinical and laboratory examination. The presence of carotid plaques was taken as carotid atherosclerosis. The covariates of carotid atherosclerosis were identified in univariate and multivariate regressions...
September 8, 2016: Clinical and Experimental Rheumatology
Mara de Moura Gondim Prata, A Havt, D T Bolick, R Pinkerton, Aam Lima, R L Guerrant
Fecal biomarkers have emerged as important tools to assess intestinal inflammation and enteropathy. The aim of this study was to investigate the correlations between the fecal markers, myeloperoxidase (MPO), lactoferrin (FL), calprotectin (FC) and lipocalin-2 (Lcn-2), and to compare differences by breastfeeding status as well as normalization by fecal protein or by fecal weight. Simultaneous, quantitative MPO, FL, FC and Lcn-2, levels were determined in frozen fecal specimens collected from 78 children (mean age 15...
2016: Journal of Translational Science
Robert N Lopez, Steven T Leach, Daniel A Lemberg, Gilles Duvoisin, Richard B Gearry, Andrew S Day
Over the last two decades knowledge on faecal biomarkers has substantially increased. Nowadays these non-invasive markers of inflammation have significant clinical utility in the management of inflammatory bowel disease (IBD). Their use informs the decision to perform endoscopy before diagnosis is made right through to influencing therapeutic choices and the need for interval endoscopic assessment. In this review, the roles of two S100 proteins, calprotectin and S100A12 are described along with that of lactoferrin, in the context of IBD...
October 10, 2016: Journal of Gastroenterology and Hepatology
Marisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, Alicia López-García, Valle García-Sánchez, Antonio López-Sanromán, Esther Hinojosa, Lucía Márquez, Santiago García-López, María Chaparro, Montserrat Aceituno, Margalida Calafat, Jordi Guardiola, Blanca Belloc, Yolanda Ber, Luis Bujanda, Belén Beltrán, Cristina Rodríguez-Gutiérrez, Jesús Barrio, José Luis Cabriada, Montserrat Rivero, Raquel Camargo, Manuel van Domselaar, Albert Villoria, Hugo Salata Schuterman, David Hervás, Pilar Nos
BACKGROUND: Ulcerative colitis (UC) treatment is focused to achieve mucosal healing, avoiding disease progression. The study aimed to evaluate the real-world effectiveness of adalimumab (ADA) in UC and to identify predictors of remission to ADA. METHODS: This cohort study used data from the ENEIDA registry. Clinical response, clinical remission, endoscopic remission, adverse events (AE), colectomy, and hospitalisations were evaluated; baseline characteristics and biological parameters were compared to determine predictors of response...
October 8, 2016: Journal of Gastroenterology
Michael A Mendall, Derek Chan, Roshani Patel, Devinder Kumar
BACKGROUND: Faecal calprotectin (FC) is one of the most widely used non-invasive tests for the diagnosis and assessment of Crohn's disease (CD) activity. Despite this, factors other than disease activity which affect levels have not been extensively reviewed. This is of importance when using FC in the diagnostic setting but also may be of utility in studying the aetiology of disease. OBJECTIVES: Our review outlines environmental risk factors that affect FC levels influencing diagnostic accuracy and how these may be associated with risk of developing CD...
October 7, 2016: BMC Gastroenterology
A Stallmach, C Langbein, R Atreya, T Bruns, A Dignass, K Ende, J Hampe, F Hartmann, M F Neurath, J Maul, J C Preiss, R Schmelz, B Siegmund, H Schulze, N Teich, U von Arnim, D C Baumgart, C Schmidt
BACKGROUND: Vedolizumab, a monoclonal antibody targeting the α4β7-integrin, is effective in inducing and maintaining clinical remission in Crohn's disease and ulcerative colitis according to randomised clinical trials. AIM: To determine the long-term effectiveness of vedolizumab in a real-world clinical setting. METHODS: This observational registry assessed the clinical outcome in patients treated with vedolizumab for clinically active Crohn's disease (n = 67) or ulcerative colitis (n = 60)...
October 7, 2016: Alimentary Pharmacology & Therapeutics
Oscar R Herrera, Michael L Christensen, Richard A Helms
As seen over the past 20 years, calprotectin has evolved as a novel, non-invasive biomarker of gastrointestinal (GI) inflammation. We present this review of calprotectin in pediatrics. This article will focus on studies using calprotectin concentrations from different body fluids to monitor inflammation in different disease states and conditions. The ultimate goal of our group is to lay down a foundation as we consider using calprotectin prospectively as a marker of intestinal inflammation that could lead to further testing and possibly a marker of preparedness for feeding...
July 2016: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
Łukasz Michalak, Magdalena Bulska, Katarzyna Kudłacz, Piotr Szcześniak
Neutrophil gelatinase-associated lipocalin, known also as 24p3 lipocalin, lipocalin-2 or uterocalin (in mouse), is a small secretory protein binding small molecular weight ligands which takes part in numerous processes including apoptosis induction in leukocytes, iron transport, smell, and prostaglandins and retinol transport [19]. It was discovered in activated neutrophils as a covalent peptide associated with human gelatinase neutrophils [7]. Neutrophil lipocalin is secreted physiologically in the digestive system, respiratory tract, renal tubular cells, liver or immunity system...
January 4, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
Marianthi Chatzikonstantinou, Panagiotis Konstantopoulos, Spyros Stergiopoulos, Konstantinos Kontzoglou, Christos Verikokos, Despina Perrea, Dimitris Dimitroulis
Inflammatory bowel diseases (IBD) are chronic intestinal disorders caused by a number of factors, including external influences, intestinal microbiota and genetics. The two major clinically defined types of IBD are Crohn's disease and ulcerative colitis, each of which is characterized by relapses in the clinical course, thus patients must be under constant observation via regular endoscopies. As endoscopy, which has been used for direct evaluation and diagnosis of IBD, requires uncomfortable and expensive bowel preparation, a non-invasive test was required to reduce the number of patients undergoing unnecessary endoscopy...
October 2016: Biomedical Reports
Vahid Basirat, Zahra Azizi, Sanam Javid Anbardan, Mina Taghizadeh Asl, Yasaman Farbod, Azam Teimouri, Nasser Ebrahimi Daryani
INTRODUCTION Due to limitation of colonoscopy in assessing the entire bowel and patients' intolerance in inflammatory bowel disease (IBD), in the current study, we aimed to prospectively compare the accuracy of (99m)Tc(V)-dimercaptosuccinic acid (DMSA) and fecal calprotectin with ileocolonoscopy as new methods for localizing inflammations. METHODS Current prospective study conducted between 2012 and 2014 on 30 patients with IBD attending Gastroenterology Clinic of Tehran University of Medical Sciences. Fecal calprotectin and disease activity were measured for all participants and all of them underwent (99m)Tc (V)-DMSA scintigraphy and colonoscopy...
July 2016: Middle East Journal of Digestive Diseases
Anna Winberg, Olga Nagaeva, Ivan Nagaev, Catarina Lundell, Ignacio Arencibia, Lucia Mincheva-Nilsson, Eva Rönmark, Christina E West
BACKGROUND: There is need for prognostic markers for symptomatic food allergy since current diagnostic methods are insufficient and/or time and labor consuming. OBJECTIVE: To estimate the cytokine mRNA profiles in peripheral blood mononuclear cells (PBMC) before and after a double-blind placebo-controlled food challenge series in schoolchildren with suspected allergy to milk, egg or cod and in healthy controls. Analyses of fecal inflammatory biomarkers before and after the challenge were included...
December 2016: Cytokine
Shunsuke Sekiya, Makoto Murata, Satoshi Arai, Hiroshi Murayama, Atushi Kawasaki, Noriyuki Ashida, Kohki Okada, Masaki Ikemoto
Calprotectin, a heterodimer of S100A8 and S100A9, has been reported to be a useful biomarker in inflammatory bowel disease (IBD); however, the relationship between the fecal level of S100A9 and the extent of inflammation in IBD remains unclear. Our aim was to develop a new enzyme-linked immunosorbent assay (ELISA) for rat S100A9, and to investigate whether changes in fecal S100A9 levels reflect the inflammatory conditions in the intestinal tracts of rats with dextran sulfate sodium (DSS)-induced colitis. Anti-rat S100A9 monoclonal antibodies were raised in mice and used for the development of a novel ELISA for rat S100A9...
September 28, 2016: Journal of Immunological Methods
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"